Table 2.
Tumour/method | Lamins A and C | Lamin B1 |
---|---|---|
Oesophageal cancer: squamous/IPO | 3/6 (a) | 3/6 (a) |
0/6 (c) | 3/6 (c) | |
3/6 (d) | 0/6 (d) | |
Oesophageal cancer: adenocarcinoma/IPO | 0/2 (a) | 1/2 (a) |
1/2 (c) | 0/2 (c) | |
1/2 (d) | 1/2 (d) | |
Oesophageal cancer cell lines/PM | 3/3 (b) | nr |
Gastric adenocarcinoma/IPO | 1/8 (a) | 2/8 (a) |
3/8 (c) | 2/8 (c) | |
4/8 (d) | 4/8 (d) | |
Colonic adenocarcinoma/IPO | 0/17 (a) | 0/17 (a) |
3/17 (c) | 10/17(c) | |
14/17(d) | 7/17 (d) | |
Colorectal cancer/IPO | 463/656 (a) | nr |
193/656 (d) | ||
Pancreatic cancer/IPO | 3/3 (a) | 3/3 (a) |
Hepatocellular cancer/IPO* | 5/5 (a) | 5/5 (a) |
IPO – Immunoperoxidase, PM – Protein microarrays.
(a) positive staining, (b) elevated staining/levels, (c) reduce staining/levels (d) no staining.
B type lamins were evaluated.